Inovio Pharmaceuticals’ (INO) Sell (E+) Rating Reaffirmed at Weiss Ratings

Inovio Pharmaceuticals (NASDAQ:INO)‘s stock had its “sell (e+)” rating restated by research analysts at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

A number of other brokerages also recently issued reports on INO. Zacks Research downgraded shares of Inovio Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 3rd. Wall Street Zen lowered shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 16th. HC Wainwright restated a “neutral” rating and issued a $3.00 price objective on shares of Inovio Pharmaceuticals in a research report on Thursday, August 14th. Finally, Piper Sandler began coverage on shares of Inovio Pharmaceuticals in a research report on Wednesday, July 9th. They set an “overweight” rating and a $5.00 price target for the company. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $8.80.

Inovio Pharmaceuticals Trading Up 7.1%

Inovio Pharmaceuticals stock opened at $2.56 on Wednesday. Inovio Pharmaceuticals has a 1-year low of $1.30 and a 1-year high of $5.83. The firm has a market capitalization of $136.05 million, a price-to-earnings ratio of -0.98 and a beta of 1.65. The firm has a 50 day simple moving average of $2.17 and a 200 day simple moving average of $1.93.

Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings data on Tuesday, August 12th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.02. On average, equities research analysts forecast that Inovio Pharmaceuticals will post -4.23 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in INO. Qube Research & Technologies Ltd purchased a new position in Inovio Pharmaceuticals in the second quarter worth $234,000. Nuveen LLC purchased a new position in Inovio Pharmaceuticals in the first quarter worth $168,000. AQR Capital Management LLC purchased a new position in Inovio Pharmaceuticals in the first quarter worth $120,000. Concurrent Investment Advisors LLC purchased a new position in Inovio Pharmaceuticals in the first quarter worth $90,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in Inovio Pharmaceuticals in the second quarter worth $86,000. 26.79% of the stock is currently owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.